Xvivo Perfusion Publishes Q3 2026 Interim Report Presentation

• Xvivo Perfusion's third-quarter 2026 sales rose 34% to SEK 253 million.
• EBITDA increased to SEK 52 million from SEK 36 million; the margin widened to 21% from 19%.
• Thoracic sales reached SEK 177 million, with organic growth of 51%.
• Nine-month sales climbed 25% to SEK 733 million.
• Heart Assist Transport secured CE marking; the FDA received its premarket approval application in September 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xvivo Perfusion AB published the original content used to generate this news brief on October 22, 2026, and is solely responsible for the information contained therein.